Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1).
Artificial neural networks (ANNs) have been widely used for medicinal chemistry modeling. In the last two decades, too many reports used MATLAB environment as an adequate platform for programming ANNs. Some of these reports comprise a variety of applications intended to quantitatively or qualitatively describe structure-activity relationships. A powerful tool is obtained when there are combined Bayesian-regularized neural networks (BRANNs) and genetic algorithm (GA): Bayesian-regularized genetic neural networks (BRGNNs). BRGNNs can model complicated relationships between explanatory variables and dependent variables. Thus, this methodology is regarded as useful tool for QSAR analysis. In order to demonstrate the use of BRGNNs, we developed a reliable method for predicting the antagonistic activity of 5-amino-3-arylisoxazole derivatives against Human Platelet Thrombin Receptor (PAR-1), using classical 3D-QSAR methodologies: Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). In addition, 3D vectors generated from the molecular structures were correlated with antagonistic activities by multivariate linear regression (MLR) and Bayesian-regularized neural networks (BRGNNs). All models were trained with 34 compounds, after which they were evaluated for predictive ability with additional 6 compounds. CoMFA and CoMSIA were unable to describe this structure-activity relationship, while BRGNN methodology brings the best results according to validation statistics.
Caballero
Julio
J
Facultad de Ingeniería en Bioinformática, Centro de Bioinformática y Simulación Molecular, Universidad de Talca, Talca, Chile. jcaballero@utalca.cl, jmcr77@yahoo.com
Fernández
Michael
M
D000465:Algorithms; D001499:Bayes Theorem; D001792:Blood Platelets / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical; D053263:Gene Regulatory Networks; D016333:HIV Protease; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D016571:Neural Networks, Computer; D021281:Quantitative Structure-Activity Relationship; D044463:Receptor, PAR-1 / Q000737:chemistry; D011966:Receptors, LHRH / Q000037:antagonists & inhibitors; D010975:Platelet Aggregation Inhibitors
D061965:Matrix Metalloproteinase Inhibitors; D044463:Receptor, PAR-1; D011966:Receptors, LHRH; D016333:HIV Protease; D010975:Platelet Aggregation Inhibitors